Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Terfenadine, a potent and non-sedative antihistamine, was shown to be effective in chronic idiopathic urticaria in a double-blind crossover placebo controlled trial. An oral twice daily 60 mg dose of terfenadine was given and itch and wheal parameters were assessed daily. Despite the overall effectiveness of terfenadine, a variable response was noted which was similar to that shown in previous studies with other antihistamines.
 ...
PMID:Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. 393 49

A single oral dose of triprolidine hydrochloride, 0.04 mg/kg (mean dose 2.7 +/- SD 0.4 mg) was administered to seven healthy, fasting adult volunteers who had never been treated previously with H1-receptor antagonists. Blood sampling and intradermal tests with 0.01 ml of histamine phosphate (0.1 mg/ml) were performed at -0.25, 1, 2, 3, 4, 5, 6, 7, 8, and 12 hours after the dose. Wheal-and-flare circumferences were traced, and the areas were measured by planimetry. Pruritus was quantitated by use of a clinical score. Urine was collected in 6-hour pooled aliquots for a total of 24 hours. Serum and urine triprolidine concentrations were measured by high-performance liquid chromatography. Wheal-and-flare areas and pruritus decreased after the triprolidine dose. Suppression of mean flare size was statistically significant at 2, 3, 6 and 8 hours. Suppression of mean wheal size was not statistically significant at any time compared to predose values. The mean triprolidine serum half-life was 2.1 +/- 0.8 hours. The mean peak serum triprolidine concentration of 15.4 +/- 8.3 ng/ml occurred 2 hours after ingestion. No triprolidine was detected in the serum after 12 hours. The mean urinary excretion of unchanged triprolidine during 24 hours was 1.3 +/- 1.0% of the dose administered.
 ...
PMID:An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects. 394 83

One of the frequently reported side effects following epidural morphine administration in clinical trials is a generalized pruritus of several hours duration. Since histamine can elicit pruritus we investigated the plasma histamine levels following epidurally applied morphine (0.05 mg/kg) in 10 urological patients. Plasma histamine levels were determined as an indicator of histamine release. Indeed, in 2 of 10 patients plasma histamine concentrations rose to 2 ng/ml. 5 of 6 criteria for establishing histamine release were fulfilled in both cases. Minor clinical symptoms appeared only in one patient (one single wheal of 1 cm diameter, metallic taste), but no symptoms at all in the other. Considering the low dose of the analgesic and the relatively high incidence of histamine release (2/10) the result of this prospective study seems worth to be emphasisized and followed-up in further studies. Pruritus did not occur in any of the patients, the role of histamine in its pathogenesis is now becoming more doubtful.
 ...
PMID:[The behavior of plasma histamine levels following peridural morphine administration]. 405 Nov 66

We studied the pharmacokinetics and antihistaminic effect of brompheniramine in seven normal adults. The mean peak serum brompheniramine concentration of 11.6 +/- 3.0 ng/ml occurred at a mean time of 3.1 +/- 1.1 hr. The mean serum half-life value was 24.9 +/- 9.3 hr, the mean clearance rate was 6.0 +/- 2.3 ml/min/kg, and the mean volume of distribution was 11.7 +/- 3.1 L/kg. The mean wheal size was significantly suppressed (p less than or equal to 0.1) at 3, 6, and 9 hr after the brompheniramine dose when mean concentrations ranged from 10.2 +/- 2.9 to 7.0 +/- 2.2 ng/ml. Significant suppression (p less than or equal to 0.05) of mean flare size was found from 3 to 48 hr after the brompheniramine dose, when mean concentrations ranged from 10.2 +/- 2.9 to 2.5 +/- 0.6 nl/ml. The mean pruritus score was significantly suppressed at 9 and 12 hr (p less than or equal to 0.1) and at 24 hr (p less than or equal to 0.05). Brompheniramine had a long half-life and large volume of distribution in normal adults. It also had a prolonged antihistaminic effect in the skin as evidenced by suppression of the wheal and flare response to histamine and by suppression of pruritus.
 ...
PMID:The pharmacokinetics and antihistaminic effects of brompheniramine. 612 58

The effect of astemizole on the weal and flare response to intradermal histamine has been studied in normal volunteers after single dosing, and in patients with urticaria and pruritus after chronic dosing with the drug. Single doses of astemizole (40 mg) in normal volunteers significantly reduced histamine weal and flare at 24 and 48 h (p less than 0.001). Before treatment, there was a significantly greater response to intradermal histamine in patients with urticaria than pruritus (p less than 0.05). Chronic dosing with astemizole produced significant reduction in histamine-induced weal and flare in both patient groups which did not show evidence of tachyphalaxis over the period of the study. The effect of astemizole on histamine-induced weal and flare was accompanied by a significant increase in the rate of weal and flare disappearance in both patients (weal p less than 0.002, flare p less than 0.05) and volunteers (weal p less than 0.02, flare p less than 0.005); but there was no change in the rate of weal formation. The effects of astemizole on weal and flare kinetics may be a function of its high level of H1 antagonist activity.
 ...
PMID:The effects of astemizole on histamine-induced weal and flare. 614 Jan 68

We studied the pharmacokinetics and the suppression of histamine-induced wheals, flares, and pruritus in the skin after administration of the histamine H1 antagonist hydroxyzine to seven healthy adults. After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr. The mean elimination half-life calculated from the terminal linear portion of the serum hydroxyzine concentration vs. time curve was 20.0 +/- 4.1 hr. The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg. The single dose of hydroxyzine suppressed pruritus at the wheal and flare sites from 1 to 36 hr. Maximal suppression of the wheals was 80% and maximal suppression of the flares was 92%. Significant suppression of the wheals and flares persisted for 36 and 60 hr, respectively. Pharmacodynamic analysis of the wheal and flare suppression data and the mean serum hydroxyzine concentrations supports the prolonged terminal serum half-life value for the drug.
 ...
PMID:The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. 614 Nov 98

Ninety patients participated in a randomised, double blind, placebo controlled comparison of terfenadine with astemizole in the treatment of hay fever. They entered the trial as a cohort before the grass pollen season and recorded daily their symptoms of itching eyes, sneezing, running nose, and blocked nose on visual analogue scales in diary cards. Over the eight weeks of the trial astemizole was significantly better than either terfenadine or placebo in alleviating itching eyes, sneezing, and running nose (p less than 0.0001) but no better than placebo for the treatment of blocked nose. The placebo was significantly better than terfenadine for the treatment of running nose and blocked nose (p less than 0.002). Neither of these H1 antihistamine drugs was associated with sedative adverse effects despite significantly inhibiting histamine induced skin weal responses. These results suggest that astemizole is a satisfactory non-sedative H1 antihistamine for maintenance treatment of hay fever. Terfenadine is ineffective by comparison.
 ...
PMID:Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. 614 5

Adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), adenosine, adenine and inosine were injected intradermally into the backs of human volunteers. ATP, ADP and AMP evoked weal and flare responses in the skin in a dose dependent manner. The rank order of potency was ATP greater than ADP greater than AMP; other metabolites were apparently inactive. The potency of ATP was approximately 0.002 times that of histamine. In the forearm, cross tachyphylaxis was demonstrated between ATP and histamine weals; also the flare due to injected ATP spread beyond a band which was applied to prevent diffusion, indicating that the flare is neurogenic. Injections of ATP and high doses of ADP produced a sensation of persistent pain, unlike histamine which produced transient pain or itch on some occasions, and saline which was without effect. The possible involvement of histamine, mast cells and prostaglandins in the response was examined. The inhibitory actions of systemic pretreatment with diphenhydramine suggests that the erythema and wealing responses to ATP are at least partly due to ATP-evoked histamine release. Indomethacin, doxantrazole and cimetidine did not alter the ATP reaction.
 ...
PMID:Adenosine triphosphate-evoked vascular changes in human skin: mechanism of action. 617 40

The axon reflex flare is a well-described dermatologic entity with historic and diagnostic value in dermatologic practice. Recent research into the role of neuropeptide mediators has elucidated a fascinating and complex interaction between biochemistry and clinical dermatology. These principles should enhance understanding of those constant dermatologic entitites, the flare, the itch, and the wheal.
 ...
PMID:The axon reflex flare. 618 73

In 20 volunteers with normal skin, itching and concomitant erythemas and wheals were produced by mechanical stimulation with a magnetic oscillation system. In a placebo-controlled, randomized double-blind study with twice cross-over, a calcium-vitamin-D-combination as single dose ampoules for peroral application was tested. A significant decrease (p less than 0,001) of the areas of erythema and wheal and itching in treated persons, compared with non-treated and placebo-treated volunteers serving for controls, is showing the antiallergic effectiveness of the tested preparation.
 ...
PMID:[Drug modification of mechanically evoked itching and the concomitant equivalents, erythema and wheals of the skin. Clinico-experimental studies]. 636 Aug 32


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>